Incyte Corp. INCY

NAS: INCY | ISIN: US45337C1027   15/09/2025
83,14 USD (+0,05%)
(+0,05%)   15/09/2025

8 maart 2025 · Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study · Persbericht

24 juli 2023 · Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease · Persbericht

7 maart 2023 · Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline · Persbericht

5 december 2022 · Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology · Persbericht

14 juni 2022 · FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata · Persbericht

20 mei 2022 · CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) · Persbericht

11 mei 2022 · FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 · Persbericht

26 maart 2022 · Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies · Persbericht

31 januari 2022 · Bedrijfsnieuws uit Amerika · Bolero.be

Net voor de beurs in de VS de deuren opent, blikken we even terug op het belangrijkste bedrijfsnieuws in Amerika. Elliott Management en Vista Equity Partners zouden Citrix Systems overnemen De Amerikaanse vermogensbeheerder...

28 januari 2022 · Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis · Persbericht

9 november 2021 · OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis · Persbericht

4 november 2021 · Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies · Persbericht

30 september 2021 · OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata · Persbericht

27 september 2021 · Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases · Persbericht

3 augustus 2021 · Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation · Persbericht

2 juni 2021 · OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses · Persbericht

23 april 2021 · OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses · Persbericht

20 april 2021 · Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study · Persbericht

8 april 2021 · Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients · Persbericht

6 april 2021 · Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis · Persbericht

Mijn selecties